Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in ankylosing spondylitis.

F Huang1, J C C Wei, M Breban

  • 1Chinese PLA General Hospital, Beijing.

Clinical and Experimental Rheumatology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining Prognostic Assessment in Elderly Non-small Cell Lung Cancer: The Importance of Dynamic Comorbidities and Comprehensive Biomarker Profiling.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

[Development and reliability and validity testing of the questionnaire on rotavirus vaccination behavioral and social drivers].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[Analysis of the willingness and related factors of pregnant women in Shanghai City to receive influenza vaccines during pregnancy].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

Evaluation of brachytherapy applicators and their association with morbidity and local control in cervix cancer: An EMBRACE I analysis.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

[Clinical study of intracranial hypotension targeted body posture combined with pharmacotherapy in the treatment of chronic subdural hematoma].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2025
Same author

[Application value of CT in the assessment of spinal structural damage in axial spondyloarthritis].

Zhonghua nei ke za zhi·2025
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Thalidomide shows promise for treating severe ankylosing spondylitis (AS), with 68% of patients improving in open studies. Despite risks like teratogenicity, its efficacy may stem from inhibiting NF-kappaB and TNFalpha.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory disease.
  • Thalidomide, despite known side effects, is being explored for AS treatment.
  • Existing treatments for severe AS have limitations.

Purpose of the Study:

  • To evaluate the efficacy and safety of thalidomide in severe ankylosing spondylitis.
  • To explore the potential mechanisms of action for thalidomide in AS.

Main Methods:

  • Open-label studies involving over 50 patients with severe AS.
  • Treatment duration ranged from 6 to 12 months.
  • Patient outcomes and drop-out rates were monitored.

Main Results:

Related Experiment Videos

  • 68% of patients demonstrated clinical improvement.
  • The overall drop-out rate was 19%.
  • Potential mechanisms include inhibition of NF-kappaB and TNFalpha.

Conclusions:

  • Thalidomide demonstrates significant efficacy in treating severe ankylosing spondylitis.
  • The observed benefits may be linked to its anti-inflammatory properties.
  • Further research is warranted to confirm efficacy and manage side effects.